Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GENE

Financiado

Cerrado

Genomic screening of the Embryo for Novel targets in the tumor Endothelium

"Several angiogenesis inhibitors are in the market for treatment of cancer, but efficiency in terms of prolongation of survival is still very moderate. This can be explained by induction of resistance to therapy, since most agents... ver más

30/04/2015

STICHTING VU

176K€

Presupuesto del proyecto: 176K€

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-04-30 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

STICHTING VU

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RESTART Refined screening for novel targets in the tumor vasculature 183K€ Cerrado

AngioGenesHD Epistasis analysis of angiogenes with high cellular definiti... 1M€ Cerrado

ONCOTRACK OncoTrack Methods for systematic next generation oncology... 31M€ Cerrado

DyMERE Dynamic mapping of epigenetic regulation during embryogenesi... 174K€ Cerrado

ONCOTRACK OncoTrack - Methods for systematic next generation oncology... 31M€ Cerrado

PID2020-115439GB-I00 FENOTIPADO CELULAR ESPACIAL DE TUMORES PARA ONCOLOGIA DIGITA... 315K€ Cerrado

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 176K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Several angiogenesis inhibitors are in the market for treatment of cancer, but efficiency in terms of prolongation of survival is still very moderate. This can be explained by induction of resistance to therapy, since most agents neutralize tumor produced growth factors. An alternative and preferred strategy would be to directly target the tumor endothelial cells, which will not easily mutate to resist treatment due to genetic stability. It is hypothesized that by mining the pool of genes that have embryo-specific functions, new and fully specific markers of tumor endothelial cells can be found. The approach will be to isolate the full transcriptome of mouse embryos at early and late developmental stages, and compare it with adult mouse isolates. The pool of purely embryo-specific genes will be screened for expression in the transcriptome of FACS sorted tumor endothelial cells. Genomic screening will be performed, by next-generation sequencing, to maximize the identification of specific genes or splice variants. Gene function will be tested by genetic loss- and gain-of-function approaches in in vitro angiogenesis assays. Transmembrane and secreted tumor endothelial specific molecules will receive priority. Endogenous binding partners will be identified by yeast 2-hybrid technology and peptide design will yield specific drugs. Also, antibodies against target molecules will be generated. Initial preclinical testing will be part of this project. Translation of the technology for treatment of patients, i.e. finding the human orthologs, and extensive preclinical testing will be beyond the scope of this project and will be subject of a new grant application."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores